Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions
Do docetaxel nanoparticles boost response in mCRPC?
Autio KA et al. JAMA Oncol. 2018 July 5. doi: 10.1001/jamaoncol.2018.2168.
Key clinical point: A docetaxel-encapsulating nanoparticle targeted against prostate-specific membrane antigen (PSMA) was safe and showed good activity in men with chemotherapy-naive metastatic castration-resistant prostate cancer (mCRPC) .
Major finding: The 6-month progression-free survival rate, the primary endpoint, was 65%.
Study details: Open-label, phase 2 trial of 42 men with mCRPC that progressed on abiraterone acetate and/or enzalutamide.
Disclosures: The study was funded by BIND Therapeutics and by grants from the National Institutes of Health, Sidney Kimmel Center for Prostate and Urologic Cancers, and the David H. Koch Prostate Cancer Research Fund. Dr. Autio had no disclosures. Several coauthors are employees of BIND Therapeutics, and others are employed by Epic Sciences, maker of the CTC assay used in the study. Other coauthors reported advising/consulting, research support, and speakers bureau activities for multiple companies.
Source: Autio KA et al. JAMA Oncol. 2018 July 5. doi: 10.1001/jamaoncol.2018.2168.
Autio KA et al. JAMA Oncol. 2018 July 5. doi: 10.1001/jamaoncol.2018.2168.